Cancer research saves lives and leads to improved outcomes for patients. But federal cancer research funding may be in jeopardy for 2026.

Background: Mantle Cell Lymphoma (MCL) is generally treated with rituximab (R) in combination with other drugs. However, treatment for relapsed or refractory (RR) MCL is challenging. For Ibrutinib ...

Study participants are enrolled in cohorts based on their tumor types (e.g., an advanced solid tumor), the genomic alterations of their tumors, and the targeted drug (s) matched to those alterations ...

The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer re ...

This paper integrates stakeholder input and identifies potential components for the forthcoming Cures 2.1 legislation. It also builds on more than 300 stakeholder responses and aims to accelerate the ...

The nomination period for the upcoming ASCO Election is now closed. ASCO staff will review recommendations to confirm eligibility of submitted names. Following the eligibility check, the ASCO ...

Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the ...

SPARGO, Inc. is the only official registration and housing provider for ASCO Meetings and Symposia. Individuals unaffiliated with ASCO or SPARGO, Inc. may entice prospective attendees into registering ...

Launched in 2016, this award program honors extraordinary women leaders in oncology and role models who have excelled as mentors and have demonstrated outstanding commitment to the development of the ...

ASCO Guidelines Assistant is an interactive AI tool developed by ASCO and Google Cloud. The tool allows oncologists to quickly search and use ASCO Guidelines through a simple, intuitive chat.

Conquer Cancer®, the ASCO Foundation and Pfizer External Research & Grants are collaborating to offer a Quality Improvement grant funding opportunity to improve the patient experience in bladder ...

The Association for Clinical Oncology (ASCO) strongly opposedan earlier effort to establish a MFN drug pricing model in Medicare, since it would have imposed a nationwide, mandatory payment model on ...